Paris, France · Est. 2004 · 91,000 employees
Global healthcare company focused on therapeutic solutions.
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Orange Book Patents
Across 4 drugs with upcoming expirations
Pipeline
By Phase
79 drugs in development
By Therapeutic Area
top 6
R&D Momentum
93/100
Pipeline Velocity
73/100
Trial Completion Rate
87/100
Pipeline Concentration
13/100
Pipeline Freshness
70/100
Strategic Signals
Activity
Last 14 days
RSV Immunisation Status in Queensland (Australia)
Long-term Extension Study to Evaluate the Safety and Efficacy of Riliprubart (SAR445088) in Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
A Phase 1/2, Study to Evaluate the Safety, Tolerability, and Efficacy of One-time Intravitreal Dose of SAR446597 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration
A Double-blinded Extension Study to Evaluate the Long-term Safety and Tolerability of Itepekimab in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Participated in Either EFC16750 or EFC16819 Clinical Studies
Prospective, Non-interventional Observational Study to Characterize Dupilumab in the Long-term Management of Eosinophilic Esophagitis, Safety and Patient Reported Outcomes (Quality of Life) in Clinical Routine
A Prospective Observational Study to Assess the Long-term Safety and Immunogenicity of Olipudase Alfa Therapy During Routine Clinical Care in Pediatric Patients Less Than 2 Years of Age With Acid Sphingomyelinase Deficiency
A Phase 2b, Randomized, Placebo-controlled, Observer-blind Study in Adults 60 Years of Age and Older to Evaluate the Efficacy, Safety, and Immunogenicity of a Bivalent Protein Vaccine Candidate Against Respiratory Syncytial Virus (RSV) and Human Metapneumovirus (HMPV)
A Phase 2b/Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study, to Investigate the Efficacy and Safety of Lunsekimig in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
A Multicenter, Multinational, Randomized, Double-blind, Placebo-Controlled, Phase 3 Maintenance Study to Evaluate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
A Phase 1/2, Parallel, Observer-blind Study to Assess the Safety and Immunogenicity of an Egg-based H5N8 Influenza Vaccine at Multiple Dose Levels Adjuvanted With Matrix-M in Healthy Participants 18 Years of Age and Above.
A Multinational, Multicenter Extension Study to Investigate the Long-term Safety, Tolerability and Efficacy of Balinatunfib in Adults With Crohn's Disease or Ulcerative Colitis
Details
Company Overview
$140.0B
Mkt Cap
$43.1B
Revenue
$11.2B
Cash
Therapeutic Focus
Pipeline
Regulatory
Lovenox — LOVENOX (PRESERVATIVE FREE), LOVENOX
Application NDA020164
Sutimlimab — ENJAYMO
Application BLA761164
Rifadin — RIFADIN
Application NDA050627
Avalglucosidase alfa — NEXVIAZYME
Application BLA761194
Rifadin — RIFADIN
Application NDA050627
Lovenox — LOVENOX (PRESERVATIVE FREE), LOVENOX
Application NDA020164
BEYFORTUS — BEYFORTUS
Application BLA761328 (BLA)
Rifadin — RIFADIN
Application NDA050627
Rifadin — RIFADIN
Application NDA050627
Sutimlimab — ENJAYMO
Application BLA761164
Rifadin — RIFADIN
Application NDA050627
glutamine — L-GLUTAMINE
Application ANDA215647
Jevtana — CABAZITAXEL
Application NDA207970 (NDA)
Sutimlimab — ENJAYMO
Application BLA761164
Rifadin — RIFADIN
Application NDA050627
Rifadin — RIFADIN
Application NDA050627
glutamine — ENDARI
Application NDA208587
glutamine — L-GLUTAMINE
Application ANDA215647
glutamine — L-GLUTAMINE
Application ANDA219722
glutamine — L-GLUTAMINE
Application ANDA219750
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)